Pelitinib

DB05524InvestigationalSmall molecule

Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Primary indication: Investigated for use/treatment in colorectal cancer and lung cancer.Curator reviewed
Formula / weight: C₂₄H₂₃ClFN₅O₂ · 467.93 g/mol (avg)
Code names: EKB-569 · WAY-EKB-569

Resolves to

Compound

UNIIX5DWL380Z6CAS257933-82-7ChEMBLCHEMBL607707ChEBI38927

Structure

InChIKeyWVUNYSQLFKLYNI-AATRIKPKSA-NSMILESCCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC1=CC(Cl)=C(F)C=C1)=C(C=N2)C#N

Targets

P00533EGFR

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pelitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account